456 related articles for article (PubMed ID: 15020150)
1. A novel polymeric chlorhexidine delivery device for the treatment of periodontal disease.
Yue IC; Poff J; Cortés ME; Sinisterra RD; Faris CB; Hildgen P; Langer R; Shastri VP
Biomaterials; 2004 Aug; 25(17):3743-50. PubMed ID: 15020150
[TBL] [Abstract][Full Text] [Related]
2. The effect of formulation variables on the characteristics of insulin-loaded poly(lactic-co-glycolic acid) microspheres prepared by a single phase oil in oil solvent evaporation method.
Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
Colloids Surf B Biointerfaces; 2009 Nov; 74(1):340-9. PubMed ID: 19717287
[TBL] [Abstract][Full Text] [Related]
3. Stabilization and encapsulation of a staphylokinase variant (K35R) into poly(lactic-co-glycolic acid) microspheres.
He JT; Su HB; Li GP; Tao XM; Mo W; Song HY
Int J Pharm; 2006 Feb; 309(1-2):101-8. PubMed ID: 16413979
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characteristics of interferon-alpha poly(lactic-co-glycolic acid) microspheres.
Yang F; Song FL; Pan YF; Wang ZY; Yang YQ; Zhao YM; Liang SZ; Zhang YM
J Microencapsul; 2010; 27(2):133-41. PubMed ID: 20121486
[TBL] [Abstract][Full Text] [Related]
5. Effects of process and formulation parameters on characteristics and internal morphology of poly(d,l-lactide-co-glycolide) microspheres formed by the solvent evaporation method.
Mao S; Shi Y; Li L; Xu J; Schaper A; Kissel T
Eur J Pharm Biopharm; 2008 Feb; 68(2):214-23. PubMed ID: 17651954
[TBL] [Abstract][Full Text] [Related]
6. Versatility of biodegradable poly(D,L-lactic-co-glycolic acid) microspheres for plasmid DNA delivery.
Díez S; Tros de Ilarduya C
Eur J Pharm Biopharm; 2006 Jun; 63(2):188-97. PubMed ID: 16697172
[TBL] [Abstract][Full Text] [Related]
7. How cyclodextrin incorporation affects the properties of protein-loaded PLGA-based microspheres: the case of insulin/hydroxypropyl-beta-cyclodextrin system.
De Rosa G; Larobina D; Immacolata La Rotonda M; Musto P; Quaglia F; Ungaro F
J Control Release; 2005 Jan; 102(1):71-83. PubMed ID: 15653135
[TBL] [Abstract][Full Text] [Related]
8. In-situ forming implants for the treatment of periodontal diseases: Simultaneous controlled release of an antiseptic and an anti-inflammatory drug.
Lizambard M; Menu T; Fossart M; Bassand C; Agossa K; Huck O; Neut C; Siepmann F
Int J Pharm; 2019 Dec; 572():118833. PubMed ID: 31715363
[TBL] [Abstract][Full Text] [Related]
9. Size and temperature effects on poly(lactic-co-glycolic acid) degradation and microreservoir device performance.
Grayson AC; Cima MJ; Langer R
Biomaterials; 2005 May; 26(14):2137-45. PubMed ID: 15576189
[TBL] [Abstract][Full Text] [Related]
10. Bupivacaine-loaded biodegradable poly(lactic-co-glycolic) acid microspheres I. Optimization of the drug incorporation into the polymer matrix and modelling of drug release.
Zhang H; Lu Y; Zhang G; Gao S; Sun D; Zhong Y
Int J Pharm; 2008 Mar; 351(1-2):244-9. PubMed ID: 18024022
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification.
Gasparini G; Kosvintsev SR; Stillwell MT; Holdich RG
Colloids Surf B Biointerfaces; 2008 Feb; 61(2):199-207. PubMed ID: 17919891
[TBL] [Abstract][Full Text] [Related]
12. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
Mundargi RC; Babu VR; Rangaswamy V; Patel P; Aminabhavi TM
J Control Release; 2008 Feb; 125(3):193-209. PubMed ID: 18083265
[TBL] [Abstract][Full Text] [Related]
13. Enhanced intracellular uptake and inhibition of NF-kappaB activation by decoy oligonucleotide released from PLGA microspheres.
De Rosa G; Maiuri MC; Ungaro F; De Stefano D; Quaglia F; La Rotonda MI; Carnuccio R
J Gene Med; 2005 Jun; 7(6):771-81. PubMed ID: 15702489
[TBL] [Abstract][Full Text] [Related]
14. Properties of poly(lactic-co-glycolic acid) nanospheres containing protease inhibitors: camostat mesilate and nafamostat mesilate.
Yin J; Noda Y; Yotsuyanagi T
Int J Pharm; 2006 May; 314(1):46-55. PubMed ID: 16551494
[TBL] [Abstract][Full Text] [Related]
15. Controlled-delivery chlorhexidine chip versus amoxicillin/metronidazole as adjunctive antimicrobial therapy for generalized aggressive periodontitis: a randomized controlled clinical trial.
Kaner D; Bernimoulin JP; Hopfenmüller W; Kleber BM; Friedmann A
J Clin Periodontol; 2007 Oct; 34(10):880-91. PubMed ID: 17850607
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of localized immunosuppression: 2. PLA microspheres for the sustained local delivery of a soft immunosuppressant.
Pinto E; Zhang B; Song S; Bodor N; Buchwald P; Hochhaus G
Pharmazie; 2010 Jun; 65(6):429-35. PubMed ID: 20614691
[TBL] [Abstract][Full Text] [Related]
17. Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles.
Kumar PS; Ramakrishna S; Saini TR; Diwan PV
Pharmazie; 2006 Jul; 61(7):613-7. PubMed ID: 16889069
[TBL] [Abstract][Full Text] [Related]
18. The sustaining effect of three polymers on the release of chlorhexidine from a controlled release drug device for root canal disinfection.
Lee DY; Spångberg LS; Bok YB; Lee CY; Kum KY
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Jul; 100(1):105-11. PubMed ID: 15953924
[TBL] [Abstract][Full Text] [Related]
19. PLGA-based drug delivery systems: importance of the type of drug and device geometry.
Klose D; Siepmann F; Elkharraz K; Siepmann J
Int J Pharm; 2008 Apr; 354(1-2):95-103. PubMed ID: 18055140
[TBL] [Abstract][Full Text] [Related]
20. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity.
Kim TH; Jiang HH; Park CW; Youn YS; Lee S; Chen X; Lee KC
J Control Release; 2011 Feb; 150(1):63-9. PubMed ID: 21062635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
